权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

I-Corps: Polymer Lung Surfactants for Neonatal Respiratory Distress Syndrome

I-Corps：聚合物肺表面活性剂治疗新生儿呼吸窘迫综合征

基本信息

批准号：
1713953
负责人：
You-Yeon Won
金额：
$ 5万
依托单位：
Purdue University
依托单位国家：
美国
项目类别：
Standard Grant
财政年份：
2017
资助国家：
美国
起止时间：
2017-01-01 至 2018-06-30
项目状态：
已结题

来源：
https://www.nsf.gov/awardsearch/showAward?AWD_ID=1713953&HistoricalAwards=false
关键词：
Corps Polymer Lung Surfactants Neonatal

项目摘要

The broader impact/commercial potential of this I-Corps project is the development of a new method of treating Respiratory Distress Syndrome (RDS). This technology utilizes a new type of therapeutic agent, called ?polymer lung surfactants?. RDS is a life-threatening condition that occurs primarily in infants who are born prematurely. The cause of RDS is the lack of chemical compounds called lung surfactants in the infant?s lungs. Currently, the standard treatment for RDS involves injection of animal-derived lung surfactant compounds into the patient?s lung. However, this animal-derived treatment has major drawbacks: (1) the harvesting process carries the risk of pathogenic contamination; (2) these conventional lung surfactants (containing proteins susceptible to denaturation) require sophisticated delivery procedures that can only be practiced in locations where skilled healthcare professionals and advanced care facilities are available. Due to these factors, RDS remains a serious problem, particularly, in under-developed countries. These significant drawbacks of the current methods offers a potential opportunity for the new polymer lung surfactant technology developed here.This I-Corps project will develop a fully synthetic material (polymers) as a cheaper replacement for costly lipid-based formulations for treatment of respiratory distress syndrome (RDS). Lung surfactant plays a critical role in the lung?s ability to process air by lowering alveolar surface tension. For potential lung surfactant applications promising candidate materials have been identified that are capable of replicating the surface-tension-lowering properties of natural lung surfactants. The research will advance understanding of how certain polymers are able to produce extremely low air-water interfacial tensions under dynamic compression (similarly to the natural lung surfactant) and what molecular factors contribute to these behaviors.

I-Corps项目的更广泛影响/商业潜力是开发一种治疗呼吸窘迫综合征（RDS）的新方法。这项技术利用了一种新型的治疗剂，称为？聚合物肺表面活性剂？RDS是一种危及生命的疾病，主要发生在早产儿中。 RDS的原因是婴儿体内缺乏一种叫做肺表面活性剂的化合物？的肺。目前，RDS的标准治疗包括向患者体内注射动物源性肺表面活性物质化合物？的肺。然而，这种动物源性治疗具有主要缺点：（1）收获过程具有致病性污染的风险;（2）这些常规肺表面活性剂（含有易变性的蛋白质）需要复杂的递送程序，其只能在熟练的医疗保健专业人员和先进的护理设施可用的地方实施。由于这些因素，RDS仍然是一个严重的问题，特别是在欠发达国家。目前方法的这些显著缺点为新的聚合物肺表面活性剂技术提供了潜在的机会。I-Corps项目将开发一种全合成材料（聚合物），作为治疗呼吸窘迫综合征（RDS）的昂贵脂质制剂的廉价替代品。肺表面活性物质在肺中起关键作用？通过降低肺泡表面张力来处理空气。对于潜在的肺表面活性剂应用，已经确定了有希望的候选材料，其能够复制天然肺表面活性剂的表面张力降低特性。该研究将促进对某些聚合物如何能够在动态压缩下产生极低的空气-水界面张力（类似于天然肺表面活性剂）以及哪些分子因素有助于这些行为的理解。